Vanda Pharmaceuticals Reports First Quarter 20...(7 5105714 Loss on disposal of...)

Date:4/29/2009

7 5,105,714 Loss on disposal of assets - 610 Amortization of net discounts on short-term investments 38,263 (162,519) Changes in assets and liabilities: Prepaid expenses and other current assets 168,728 606,421 Accounts payable 903,002 (1,355,101) Accrued expenses (833,198) (1,299,209) Other liabilities 1,021 68,365 ----- ------ Net cash used in operating activities (3,794,730) (16,109,219) ---------- ----------- Cash flows from investing activities: Purchases of property and equipment - (186,442) Purchases of marketable securities (5,077,656) (1,485,150) Proceeds from sales of marketable securities 126,547 2,790,026 Maturities of marketable securities 3,500,000 29,060,000 --------- ---------- Net cash provided by (used in) investing activities (1,451,109) 30,178,434 ---------- ---------- Cash flows from financing activities: Net cash provided by ----- ------ financing activities - - ----- ------ Effect of foreign currency translation - 16,745 ----- ------ Net change in cash and cash equivalents (5,245,839) 14,085,960 Cash and ca
'/>"/>

SOURCE Vanda Pharmaceuticals Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10
Related biology technology :

1. Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2008 Results
2. Vanda Pharmaceuticals Reports Third Quarter 2008 Results
3. Vanda Pharmaceuticals Declares Dividend Distribution of Preferred Stock Purchase Rights
4. Vanda Pharmaceuticals to Announce Second Quarter 2008 Financial Results on August 5, 2008
5. LabCorp(R) and Vanda Pharmaceuticals Collaborate to Offer Genetic Tests
6. Vanda Pharmaceuticals to Present at the Bank of America 2008 Healthcare Conference
7. Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Results
8. Onyx Pharmaceuticals Announces First Quarter 2009 Financial Results Teleconference and Webcast
9. Transcept Pharmaceuticals to Present at the Bank of America and Merrill Lynch 2009 Health Care Conference
10. Inimex Pharmaceuticals begins First Clinical Study of an Innate Defense Regulator
11. Cadence Pharmaceuticals Announces Presentations at Upcoming Scientific Conferences